Optimer Pharmaceuticals Announces Funding

San Diego-based Optimer Pharmaceuticals said that it has raised $34.2M in two rounds of venture funding. The latest funding of $22.2M, closed November 30th, and included investments from ProQuest Investments, Lurie Investments, BB Biotech Ventures, SB Life Science Ventures, UOB JAIC Venture Bio Investments, as well as China Development Industrial Bank, ESun Bank Group, Fubon Financial Holding Venture, Global Strategic Investments, Oriental Union Chemical Corp., and Taiwan Global BioFund. The company also disclosed a Series C financing round of $12M from Par Pharmaceutical in April of 2005. Optimer is developing a narrow spectrum antibiotic in the biopharmaceuticals area. More information »